Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128784) titled 'Effect of Combining Liraglutide with the "5:2" Intermittent Fasting Diet on Weight and Body Composition in Participants Discontinuing Weekly Weight-Loss Therapeutics (LIFE)' on July 26.
Study Type: Interventional study
Study Design:
Cross-over
Primary Sponsor: Nanjing Drum Tower Hospital
Condition:
Overweight or Obesity
Intervention:
Group B:After receiving 12 weeks of liraglutide injections combined with 5:2 intermittent fasting, then receive 12 weeks of conventional lifestyle education.
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-08-01
Target Sample Size: Group B:500;...